Meet International and Domestic Experts Discussing High Potent Drugs at CPhI's High Potent Drugs 2013 Conference
MUMBAI, January 3, 2013 /PRNewswire/ --
Only Event in India Bringing Heads of High Potent Drug Manufacturing and R&D Together
High potent active pharmaceutical ingredient (HPAPI) market is rapidly growing a very strong foothold in Indian pharmaceutical industry. As per the industry experts, high potent drug is a niche area which requires a clear understanding regarding the entire process of development and manufacturing. As it involves complexities in terms of handling and safety issues, there are stringent regulatory requirements which have been evolving with time. These criteria again require a thorough knowledge.
Click here to read few industry articles on high potent drugs.
(Logo: http://photos.prnewswire.com/prnh/20130102/586364)
To discuss similar issues, CPhI's High Potent Drugs 2013, a 3-day strategic forum, is being conducted from 23-25 January 2013 at The Holiday Inn Mumbai International Airport, India.
This strategic meet covers a wide gamut of topics that concern advances in high potent drug development, manufacturing and facility design to ensure swift market introduction of cost-effective and consistent quality high potent drugs.
At High Potent Drugs 2013, senior industry experts such as Justin Mason from Safebridge, Dean Calhoun from Affygility Solutions, Rino Coladangelo from Rephine, Dr. Bhaswath Chakraborty from Cadila Pharmaceuticals, Jatin Gajjar from Famy Care and many others will share valuable insights on significant approaches in the high potent drug domain.
High Potent Drugs 2013 will also bring together Presidents, Directors, Heads of R&D, Manufacturing, Formulations and Containment Equipment from across the globe.
To know more about High Potent Drugs 2013 conference, click here.
About UBM India:
UBM India is a subsidiary of UBM plc, which is the second largest independent exhibition organiser in the world. It is the largest trade exhibition organiser in India, responsible for 26 exhibitions in different locations across the country. The company is also involved in the organisation of conference programmes throughout India and in the publications of trade journals and magazines. For further details please visit the UBM India website, http://www.ubmindia.in.
Primary Media Contact: Shrutika Shetty, shrutika.shetty@ubm.com, 91-9833344815
Secondary Media Contact: Neha Hadkar, neha.hadkar@ubm.com, 91-22-61727077
SOURCE UBM India Pvt. Ltd.
More by this Source
UBM India and MJDMA Announce First Ever Mega B2C Jewellery Fair in Chennai - 'I Love Jewellery'
20 Mar, 2013, 12:10 GMT
GJIIE 2013 Day 2 Receives Astounding Response
18 Mar, 2013, 08:03 GMT
First League of Speakers Presenting at TFM&A India's Third Edition Announced
13 Mar, 2013, 08:11 GMT
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos and customised feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.

Until you hear the full story, why would you invest?
Making sound investment decisions can be difficult. You can study the figures and read the analyst recommendations, but how do you really know the story behind company strategy? How can you get answers to your questions?
The Private Investor Network helps you to reach an informed decision on the stocks you pick. Interactive presentations from UK listed companies give you the kind of access previously enjoyed only by the big fund managers. And with keynote speeches from industry experts, downloadable content and an investor lounge where you can swap tips with your peers, you can invest with confidence.
For more information, and to register for FREE, visit us at www.privateinvestornetwork.co.uk
Next in Biotechnology News
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Start today.
Contact PR Newswire
Send us an email at MarketingUK@prnewswire.co.uk or call us at +44 (0)20 7454 5382
Become a PR Newswire client
Request more information about PR Newswire products & services or call us at +44 (0)20 7454 5382





